FDA Approves Gloucester Pharmaceuticals’ ISTODAX® for Patients with Cutaneous T-cell Lymphoma

GraphicGraphic

Back to: News Release
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. (Graphic: Business Wire)
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. (Graphic: Business Wire)

Download Formats

Share This Graphic

URL:

Smart Multimedia Gallery

Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. (Graphic: Business Wire)
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. (Graphic: Business Wire)Graphic

Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. (Graphic: Business Wire)

http://www.businesswire.com/multimedia/home/20091105006532/en/1877563/FDA-Approves-Gloucester-Pharmaceuticals%E2%80%99-ISTODAX%C2%AE-Patients-Cutaneous
http://www.businesswire.com/multimedia/home/20091105006532/en/1877563/FDA-Approves-Gloucester-Pharmaceuticals%E2%80%99-ISTODAX%C2%AE-Patients-CutaneousLogo

Download Formats

More